DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass. — IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Firm”), a clinical-stage firm creating a portfolio of immune-educating therapies based mostly on its novel DPX platform to deal with stable and hematologic cancers, right now introduced that its Board of Administrators has elected Michael P. Bailey, President and Chief Govt Officer of AVEO Oncology, to Chairman of the Board, efficient Might 1, 2022. Mr. Bailey has served on the IMV Board of Administrators since 2020 and chairs the governance committee, in addition to serving as a member of the audit and medical governance committees. Read More